Here we will take a look into some valuation metrics for Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX shares.
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has a Price to Book ratio of 3.502164. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of -3.669754, and a current Price to Earnings ratio of -3.490010. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.
Many investors rely on technical analysis when making market decisions. Technical analysis enables investors to examine previous market activity to try and predict future stock price movement. Stock prices often move in trends that can be observed. A trend may remain in place until a specific technical line is breached. Many traders will develop strategies based on defined trends. Some investors will develop opposite strategies that tend to go against the trend. Many technical chart watchers are interested in finding patterns that may repeat in the future. Repetitive price movements have been studied for a long time. Investors may choose to develop highly complex systems for trading equities, while others may choose to follow simple trend lines to identify entry and exit points. Mastering the art of technical analysis may take a long time. Developing technical skills may be a very useful tool for the investor to add to the kit.
In taking a look at some additional key numbers, Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has a current ERP5 Rank of 17271. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.
The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 3.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) currently has a Montier C-score of -1.00000. This indicator was developed by James Montier in an attempt to identify firms that were fixing the books in order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has an M-score Beneish of -3.520773. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.
Traders often key in on technical support and resistance levels when undertaking stock analysis. These levels can play an important role on a day to day basis. Many traders and investors will carefully monitor different support and resistance levels in order to gauge stock price movement. Investors may also be tracking stock price momentum. Sometimes investors may be hesitant to jump into the market after it has consistently kept heading higher over a sustained period of time. However, there may also be ample evidence that the market may just keep going higher. Markets that make new highs may have the ability to make even higher highs, thus leading to further gains. Often times, investors may be looking at technical indicators to help define trend conditions. Generally speaking, strong momentum is typically spotted near the beginning of a trend. On the flip side, momentum tends to be weaker as the trend is ending and possibly about to reverse direction.
The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 97. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 97.
At the time of writing, Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) has a Piotroski F-Score of 2. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.
Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) presently has a current ratio of 6.24. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.
The Earnings to Price yield of Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX is -0.286532. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Syndax Pharmaceuticals, Inc. NasdaqGS:SNDX is -0.404476. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is -0.177942.
Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is -0.070559. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 0.690495. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.
Investors often have to decide whether to follow the crowd or go against the herd. This can be difficult considering all the different market factors in play. Investors who strictly follow the technical charts may be missing the other half of the picture involving company fundamentals. On the other hand, investors who only look at fundamentals may be missing key information presented by studying the numbers. Combining both techniques may prove to be a solid option for researching the equity market. Many investors will opt to pick certain stocks based on fundamental analysis, and then use technical charts to figure out the proper time to make a move.
Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 80.534300. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX) is 58.170100. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 67.925700.
As the second half of the year has approached, investors may be doing a deep dive into the portfolio to see what has worked and what hasn’t worked so far this year. Investors may be looking to make a complete overhaul or just a few minor tweaks. The big question seems to be whether or not the market will remain solid of the next couple of quarters. There are obviously those who think a stock market collapse is imminent, and those who believe the market is bound for newer, greater heights. Being prepared for any scenario will most likely be greatly beneficial to individual investors over the next few months.
This post was originally published on *this site*